Denali Therapeutics (DNLI) Stock Forecast, Price Target & Predictions
DNLI Stock Forecast
Denali Therapeutics stock forecast is as follows: an average price target of $40.00 (represents a 59.68% upside from DNLI’s last price of $25.05) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
DNLI Price Target
The average price target for Denali Therapeutics (DNLI) is $40.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $22.00. This represents a potential 59.68% upside from DNLI's last price of $25.05.
DNLI Analyst Ratings
According to 7 Wall Street analysts, Denali Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DNLI stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 1 'Hold' (14.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Denali Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 01, 2024 | Michael Yee | Jefferies | $45.00 | $27.05 | 66.36% | 79.64% |
| Oct 14, 2024 | Thomas Shrader | BTIG | $35.00 | $28.00 | 25.00% | 39.72% |
| Sep 04, 2024 | Tazeen Ahmad | Bank of America Securities | $29.00 | $25.12 | 15.45% | 15.77% |
| Sep 03, 2024 | Marank Mamtani | B.Riley Financial | $33.00 | $25.12 | 31.37% | 31.74% |
| Sep 03, 2024 | Salveen Richter | Goldman Sachs | $46.00 | $25.12 | 83.12% | 83.63% |
| Sep 03, 2024 | Paul Mattels | Stifel Nicolaus | $22.00 | $25.12 | -12.42% | -12.18% |
| Aug 05, 2021 | Salveen Richter | Goldman Sachs | $112.00 | $52.93 | 111.60% | 347.11% |
| May 18, 2021 | Esther Rajavelu | UBS | $70.00 | $55.51 | 26.10% | 179.44% |
The latest Denali Therapeutics stock forecast, released on Nov 01, 2024 by Michael Yee from Jefferies, set a price target of $45.00, which represents a 66.36% increase from the stock price at the time of the forecast ($27.05), and a 79.64% increase from DNLI last price ($25.05).
Denali Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 6 | 6 |
| Avg Price Target | $45.00 | $35.00 | $35.00 |
| Last Closing Price | $25.05 | $25.05 | $25.05 |
| Upside/Downside | 79.64% | 39.72% | 39.72% |
In the current month, the average price target of Denali Therapeutics stock is $45.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 79.64% increase as opposed to Denali Therapeutics's last price of $25.05. This month's average price target is up 28.57% compared to last quarter, and up 28.57% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 01, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 14, 2024 | BTIG | Buy | Buy | Hold |
| Oct 11, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 07, 2024 | Cantor Fitzgerald | - | Neutral | Downgrade |
| Sep 03, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Feb 29, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Feb 28, 2024 | Wedbush | Buy | Buy | Hold |
| Feb 28, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Sep 06, 2023 | B. Riley Securities | - | Buy | Initialise |
| Dec 05, 2022 | Cowen & Co. | - | Outperform | Initialise |
Denali Therapeutics's last stock rating was published by Jefferies on Nov 01, 2024. The company gave DNLI a "Buy" rating, the same as its previous rate.
Denali Therapeutics Financial Forecast
Denali Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.27M | - | $35.14M | $10.28M | $3.56M | $52.48M | $42.14M | $12.51M | $5.29M | $22.94M | $7.92M | $316.81M | $9.39M | $5.85M | $3.60M | $4.67M | $13.60M | $4.20M | $4.21M | $641.00K |
| Avg Forecast | $26.74M | $36.90M | $4.17M | $4.17M | $13.40M | $6.30M | $10.00M | $14.02M | $7.98M | $11.16M | $39.51M | $28.72M | $13.12M | $17.02M | $44.66M | $33.36M | $44.82M | $30.28M | $27.92M | $31.62M | $78.21M | $494.27M | $3.67M | $5.01M | $8.62M | $9.33M | $3.35M | $9.12M | $73.96K |
| High Forecast | $30.19M | $41.66M | $4.70M | $4.70M | $17.84M | $6.32M | $10.00M | $14.02M | $20.81M | $11.16M | $44.61M | $32.43M | $14.81M | $17.02M | $44.66M | $33.36M | $44.82M | $30.28M | $27.92M | $31.62M | $78.21M | $494.27M | $3.67M | $5.01M | $8.62M | $9.33M | $3.35M | $9.12M | $88.75K |
| Low Forecast | $20.64M | $28.48M | $3.22M | $3.22M | $5.55M | $6.28M | $10.00M | $14.02M | $901.86K | $11.16M | $30.49M | $22.17M | $10.12M | $17.02M | $44.66M | $33.36M | $44.82M | $30.28M | $27.92M | $31.62M | $78.21M | $494.27M | $3.67M | $5.01M | $8.62M | $9.33M | $3.35M | $9.12M | $59.17K |
| # Analysts | 1 | 1 | 1 | 3 | 8 | 4 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.11% | - | 1.22% | 0.78% | 0.21% | 1.18% | 1.26% | 0.28% | 0.17% | 0.82% | 0.25% | 4.05% | 0.02% | 1.59% | 0.72% | 0.54% | 1.46% | 1.25% | 0.46% | 8.67% |
Denali Therapeutics's average Quarter revenue forecast for Dec 23 based on 11 analysts is $7.98M, with a low forecast of $901.86K, and a high forecast of $20.81M. DNLI's average Quarter revenue forecast represents a 530.22% increase compared to the company's last Quarter revenue of $1.27M (Sep 23).
Denali Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 8 | 4 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-113.80M | - | $-120.81M | $-101.25M | $-105.34M | $-59.34M | $-64.42M | $-73.74M | $-82.40M | $-58.49M | $-67.93M | $247.83M | $-56.02M | $-56.53M | $-54.79M | $-51.90M | $-44.48M | $-57.01M | $-36.59M | $-22.82M |
| Avg Forecast | $-17.96M | $-24.78M | $-2.80M | $-2.80M | $-9.00M | $-4.23M | $-6.72M | $-73.40M | $-5.36M | $-7.49M | $-26.53M | $-66.73M | $-43.53M | $-11.43M | $-29.99M | $-60.66M | $-30.10M | $-20.33M | $-18.75M | $-42.54M | $-52.52M | $-331.92M | $-2.46M | $-56.71M | $-5.79M | $-6.26M | $-2.25M | $-35.67M | $-136.94M |
| High Forecast | $-13.86M | $-19.12M | $-2.16M | $-2.16M | $-3.73M | $-4.22M | $-6.72M | $-58.72M | $-605.62K | $-7.49M | $-20.48M | $-53.39M | $-34.82M | $-11.43M | $-29.99M | $-48.53M | $-30.10M | $-20.33M | $-18.75M | $-34.04M | $-52.52M | $-331.92M | $-2.46M | $-45.37M | $-5.79M | $-6.26M | $-2.25M | $-28.54M | $-109.56M |
| Low Forecast | $-20.27M | $-27.98M | $-3.16M | $-3.16M | $-11.98M | $-4.24M | $-6.72M | $-88.09M | $-13.98M | $-7.49M | $-29.95M | $-80.08M | $-52.23M | $-11.43M | $-29.99M | $-72.80M | $-30.10M | $-20.33M | $-18.75M | $-51.05M | $-52.52M | $-331.92M | $-2.46M | $-68.05M | $-5.79M | $-6.26M | $-2.25M | $-42.81M | $-164.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | 15.19% | - | 1.81% | 2.33% | 9.22% | 1.98% | 1.06% | 2.45% | 4.05% | 3.12% | 1.60% | -4.72% | 0.17% | 22.94% | 0.97% | 8.97% | 7.10% | 25.33% | 1.03% | 0.17% |
7 analysts predict DNLI's average Quarter EBITDA for Mar 21 to be $-42.54M, with a high of $-34.04M and a low of $-51.05M. This is -117.17% lower than Denali Therapeutics's previous annual EBITDA (Dec 20) of $247.83M.
Denali Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 8 | 4 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | $-99.35M | - | $-88.70M | $-98.68M | $-99.11M | $-58.79M | $-63.94M | $-75.26M | $-84.59M | $-60.69M | $-70.04M | $244.88M | $-58.23M | $-58.76M | $-56.76M | $-54.02M | $-46.26M | $-58.34M | $-38.99M | $-23.68M |
| Avg Forecast | $-114.16M | $-105.53M | $-133.49M | $-138.31M | $-138.08M | $-100.84M | $-119.04M | $-75.82M | $-136.24M | $-137.22M | $-117.65M | $-68.93M | $-44.42M | $-135.36M | $-88.03M | $-62.66M | $-83.90M | $-78.44M | $-69.12M | $-43.86M | $-15.78M | $531.26M | $-102.42M | $-58.75M | $-97.52M | $-94.88M | $-77.66M | $-38.02M | $-142.07M |
| High Forecast | $-80.29M | $-74.22M | $-93.89M | $-123.16M | $-79.40M | $-70.92M | $-83.72M | $-60.66M | $-117.97M | $-96.51M | $-82.75M | $-55.14M | $-35.54M | $-135.36M | $-88.03M | $-50.13M | $-83.90M | $-78.44M | $-69.12M | $-35.09M | $-15.78M | $531.26M | $-102.42M | $-47.00M | $-97.52M | $-94.88M | $-77.66M | $-30.41M | $-113.65M |
| Low Forecast | $-133.31M | $-123.24M | $-155.90M | $-157.26M | $-167.42M | $-117.76M | $-139.01M | $-90.99M | $-159.50M | $-160.25M | $-137.40M | $-82.71M | $-53.31M | $-135.36M | $-88.03M | $-75.19M | $-83.90M | $-78.44M | $-69.12M | $-52.64M | $-15.78M | $531.26M | $-102.42M | $-70.51M | $-97.52M | $-94.88M | $-77.66M | $-45.62M | $-170.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.72% | - | 1.29% | 2.22% | 0.73% | 0.67% | 1.02% | 0.90% | 1.08% | 0.88% | 1.60% | -15.52% | -0.11% | 0.57% | 0.97% | 0.55% | 0.49% | 0.75% | 1.03% | 0.17% |
Denali Therapeutics's average Quarter net income forecast for Mar 21 is $-43.86M, with a range of $-52.64M to $-35.09M. DNLI's average Quarter net income forecast represents a -117.91% decrease compared to the company's last Quarter net income of $244.88M (Dec 20).
Denali Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 8 | 4 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | $25.32M | - | $27.14M | $23.52M | $23.26M | $21.16M | $22.54M | $21.76M | $19.32M | $19.05M | $18.94M | $17.99M | $15.80M | $13.97M | $12.55M | $10.88M | $11.21M | $15.08M | $9.31M | $5.57M |
| Avg Forecast | $25.10M | $34.64M | $3.91M | $3.91M | $12.58M | $5.91M | $9.39M | $13.16M | $7.50M | $10.47M | $37.08M | $23.82M | $12.84M | $15.80M | $41.47M | $21.66M | $41.62M | $28.11M | $25.92M | $11.86M | $72.62M | $458.97M | $3.41M | $4.65M | $8.00M | $8.66M | $3.11M | $9.08M | $68.68K |
| High Forecast | $28.34M | $39.11M | $4.42M | $4.42M | $16.75M | $5.93M | $9.39M | $13.16M | $19.54M | $10.47M | $41.87M | $28.59M | $15.41M | $15.80M | $41.47M | $25.99M | $41.62M | $28.11M | $25.92M | $14.23M | $72.62M | $458.97M | $3.41M | $4.65M | $8.00M | $8.66M | $3.11M | $10.89M | $82.41K |
| Low Forecast | $19.37M | $26.73M | $3.02M | $3.02M | $5.21M | $5.90M | $9.39M | $13.16M | $846.58K | $10.47M | $28.62M | $19.06M | $10.27M | $15.80M | $41.47M | $17.33M | $41.62M | $28.11M | $25.92M | $9.49M | $72.62M | $458.97M | $3.41M | $4.65M | $8.00M | $8.66M | $3.11M | $7.26M | $54.94K |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.42% | - | 1.14% | 1.83% | 1.47% | 0.51% | 1.04% | 0.52% | 0.69% | 0.73% | 1.60% | 0.25% | 0.03% | 4.10% | 2.70% | 1.36% | 1.29% | 4.85% | 1.03% | 81.10% |
Denali Therapeutics's average Quarter SG&A projection for Dec 23 is $7.50M, based on 11 Wall Street analysts, with a range of $846.58K to $19.54M. The forecast indicates a -70.40% fall compared to DNLI last annual SG&A of $25.32M (Sep 23).
Denali Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 8 | 4 | 5 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 10 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.72 | - | $-0.65 | $-0.74 | $-0.80 | $-0.48 | $-0.52 | $-0.62 | $-0.69 | $-0.50 | $-0.58 | $2.04 | $-0.54 | $-0.56 | $-0.55 | $-0.56 | $-0.48 | $-0.61 | $-0.41 | $-0.26 |
| Avg Forecast | $-0.67 | $-0.62 | $-0.79 | $-0.82 | $-0.81 | $-0.60 | $-0.70 | $-0.69 | $-0.80 | $-0.81 | $-0.69 | $-0.70 | $-0.79 | $-0.80 | $-0.52 | $-0.51 | $-0.50 | $-0.46 | $-0.41 | $-0.34 | $-0.09 | $3.15 | $-0.61 | $-0.57 | $-0.58 | $-0.56 | $-0.46 | $-0.40 | $-0.18 |
| High Forecast | $-0.47 | $-0.44 | $-0.55 | $-0.73 | $-0.47 | $-0.42 | $-0.49 | $-0.49 | $-0.70 | $-0.57 | $-0.49 | $-0.49 | $-0.55 | $-0.80 | $-0.52 | $-0.51 | $-0.50 | $-0.46 | $-0.41 | $-0.34 | $-0.09 | $3.15 | $-0.61 | $-0.57 | $-0.58 | $-0.56 | $-0.46 | $-0.40 | $-0.14 |
| Low Forecast | $-0.79 | $-0.73 | $-0.92 | $-0.93 | $-0.99 | $-0.69 | $-0.82 | $-0.81 | $-0.94 | $-0.95 | $-0.81 | $-0.82 | $-0.92 | $-0.80 | $-0.52 | $-0.51 | $-0.50 | $-0.46 | $-0.41 | $-0.34 | $-0.09 | $3.15 | $-0.61 | $-0.57 | $-0.58 | $-0.56 | $-0.46 | $-0.40 | $-0.22 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.89% | - | 0.93% | 0.94% | 1.00% | 0.92% | 1.02% | 1.25% | 1.49% | 1.22% | 1.71% | -21.83% | -0.17% | 0.92% | 0.96% | 0.97% | 0.85% | 1.33% | 1.02% | 1.44% |
According to 7 Wall Street analysts, Denali Therapeutics's projected average Quarter EPS for Mar 21 is $-0.34, with a low estimate of $-0.34 and a high estimate of $-0.34. This represents a -116.65% decrease compared to DNLI previous annual EPS of $2.04 (Dec 20).
Denali Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| HOWL | Werewolf Therapeutics | $1.77 | $12.00 | 577.97% | Buy |
| BDTX | Black Diamond Therapeutics | $2.62 | $14.75 | 462.98% | Buy |
| FDMT | 4D Molecular Therapeutics | $8.83 | $41.00 | 364.33% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.31 | $38.80 | 191.51% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| STOK | Stoke Therapeutics | $12.03 | $30.60 | 154.36% | Buy |
| LEGN | Legend Biotech | $38.19 | $82.69 | 116.52% | Buy |
| SWTX | SpringWorks Therapeutics | $36.45 | $67.33 | 84.72% | Buy |
| DSGN | Design Therapeutics | $5.80 | $9.67 | 66.72% | Buy |
| AKRO | Akero Therapeutics | $28.09 | $46.00 | 63.76% | Buy |
| DNLI | Denali Therapeutics | $25.05 | $40.00 | 59.68% | Buy |
| ASND | Ascendis Pharma | $126.51 | $190.21 | 50.35% | Buy |
| PCVX | Vaxcyte | $86.83 | $124.00 | 42.81% | Buy |
| BGNE | BeiGene | $189.23 | $255.80 | 35.18% | Buy |
| RNA | Avidity Biosciences | $42.18 | $54.50 | 29.21% | Buy |
| BPMC | Blueprint Medicines | $88.69 | $109.71 | 23.70% | Buy |
| TVTX | Travere Therapeutics | $17.72 | $21.75 | 22.74% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $55.13 | $60.63 | 9.98% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |